Skip to main content
Cancer Cell International logoLink to Cancer Cell International
. 2021 Mar 25;21:183. doi: 10.1186/s12935-021-01876-1

Correction to: Human drug efflux transporter ABCC5 confers acquired resistance to pemetrexed in breast cancer

Jihui Chen 1,#, Zhipeng Wang 2,#, Shouhong Gao 2, Kejin Wu 3, Fang Bai 3, Qiqiang Zhang 1, Hongyu Wang 1, Qin Ye 1, Fengjing Xu 2, Hong Sun 4, Yunshu Lu 3,, Yan Liu 1,
PMCID: PMC7995568  PMID: 33765996

Correction to: Cancer Cell Int (2021) 21:136 https://doi.org/10.1186/s12935-021-01842-x

Following publication of the original article [1], we were notified that the email address of Yan Liu should show before the one of Yunshu Lu.

The original article has been corrected.

Footnotes

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Jihui Chen and Zhipeng Wang contributed equally to this work

Contributor Information

Yunshu Lu, Email: Luyunshu@xinhuamed.com.cn.

Yan Liu, Email: liuyan03@xinhuamed.com.cn.

Reference

  • 1.Chen J, Wang Z, Gao S, Wu K, Bai F, Zhang Q, Wang H, Ye Q, Xu F, Sun H, Lu Y, Liu Y. Human drug efflux transporter ABCC5 confers acquired resistance to pemetrexed in breast cancer. Cancer Cell Int. 2021;21:136. doi: 10.1186/s12935-021-01842-x. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Cancer Cell International are provided here courtesy of BMC

RESOURCES